Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:oxycodone
gptkb:naloxone |
| gptkbp:alternativeName |
gptkb:Targin
Targiniq |
| gptkbp:approvedBy |
gptkb:United_Kingdom
|
| gptkbp:ATCCode |
N02AA55
|
| gptkbp:broadcastOn |
prescription only
|
| gptkbp:combinationTherapy |
yes
|
| gptkbp:form |
prolonged-release tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Targinact
|
| gptkbp:marketedAs |
gptkb:Napp_Pharmaceuticals
|
| gptkbp:prevention |
opioid-induced constipation
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:usedFor |
pain management
|
| gptkbp:bfsParent |
gptkb:Mundipharma_Distribution_GmbH
gptkb:Mundipharma_International_Limited |
| gptkbp:bfsLayer |
8
|